Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR1900027789Phase 4Not yet recruiting
Phase 4, randomised, open-label trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Complete remission rate and Overall response rate. Planned start Dec 2019; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR1900027789.